MODICON 28
LOE ApproachingNDAORAL-28TABLET
Approved
May 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 14h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MODICON 28 is an oral tablet small-molecule NDA approved in 1976 by Johnson & Johnson. The generic name and mechanism of action are not publicly disclosed in available data, limiting characterization of therapeutic indication and patient population.
LOE Approaching
As a nearly 50-year-old product approaching loss of exclusivity with moderate competitive pressure (30/100), this brand faces contraction and will likely operate with a lean, maintenance-focused team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate minimal hiring activity on this product. Career prospects are limited to maintenance and wind-down roles within a contracting team managing a legacy asset approaching generic competition.
Brand Manager (Lifecycle Management)Field Sales Representative
Worked on MODICON 28 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.